Zenas Biopharma (NASDAQ:ZBIO) Receives “Buy” Rating from HC Wainwright
Zenas Biopharma (NASDAQ:ZBIO – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 186.53% from the company’s current price. A number of […]
More Stories
Oppenheimer Asset Management Inc. Lowers Holdings in Motorola Solutions, Inc. (NYSE:MSI)
Oppenheimer Asset Management Inc. trimmed its stake in Motorola Solutions, Inc. (NYSE:MSI – Free Report) by 3.4% during the 1st...
Oppenheimer Asset Management Inc. Increases Stock Position in McKesson Corporation (NYSE:MCK)
Oppenheimer Asset Management Inc. raised its position in McKesson Corporation (NYSE:MCK – Free Report) by 54.0% in the first quarter,...
Supacell Season 2 Release Date, Cast, Plot & Netflix Updates
The much-awaited date announcement of Supacell Season 2 is finally here. The out-of-the-box series has already created a global buzz...
Oppenheimer Asset Management Inc. Acquires 3,962 Shares of Intel Corporation (NASDAQ:INTC)
Oppenheimer Asset Management Inc. increased its stake in Intel Corporation (NASDAQ:INTC – Free Report) by 2.7% in the 1st quarter,...
Meta Platforms, Inc. (NASDAQ:META) Shares Acquired by Brown Lisle Cummings Inc.
Brown Lisle Cummings Inc. boosted its holdings in Meta Platforms, Inc. (NASDAQ:META – Free Report) by 8.1% in the first...
Spinnaker Investment Group LLC Has $582,000 Position in Meta Platforms, Inc. (NASDAQ:META)
Spinnaker Investment Group LLC raised its stake in shares of Meta Platforms, Inc. (NASDAQ:META – Free Report) by 41.7% during...